WO2002012557A1 - Procede de detection de mutations connues en tube - Google Patents
Procede de detection de mutations connues en tube Download PDFInfo
- Publication number
- WO2002012557A1 WO2002012557A1 PCT/FR2001/002574 FR0102574W WO0212557A1 WO 2002012557 A1 WO2002012557 A1 WO 2002012557A1 FR 0102574 W FR0102574 W FR 0102574W WO 0212557 A1 WO0212557 A1 WO 0212557A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutation
- tubes
- probe
- exonuclease
- support
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
Definitions
- the present invention relates to a method for detecting a mutation in a target nucleic acid comprising amplification of the target DNA, specific hybridization of a probe with the target DNA, extension of the probe with selective addition of an ⁇ S-phosphothioatedésoxynucleotide complementary to the mutation in a tube A and addition of an ⁇ S-phosphothioatedésoxynucleotide complementary to the natural base corresponding to said mutation in a tube B; the probe thus extended being resistant to digestion by an exonuclease, in particular by exonuclease III.
- the detection of the mutation and of the natural base is carried out by direct or indirect measurement in tubes A and B.
- Mutations in germ cells or in somatic lines can have dreadful consequences on the organism, for example by causing hereditary genetic diseases or the appearance of cancer.
- the effect of a mutation is closely linked to its location in DNA. In the case of a mutation in a coding region, the loss of the function of the coded protein can be observed. If the mutation is in a regulatory region, DNA expression can be abolished or increased.
- a mutation in a gene involved in cancer in the germ line does not necessarily mean that the individual concerned will actually contract a tumor, but only that the risk of it is increased.
- the objective underlying the present invention has been to develop a technique allowing the rapid and easy determination of nucleotides to be identified and consequently the diagnosis of mutations and polymorphisms of genes, or the identification of pathogenic microorganisms or genetically modified. More specifically, the problem lies in a compilation of different techniques combining, within the same tube, the amplification of the DNA of a sample and the detection of a given nucleotide. This method is easy to use, generates signals that do not require tedious processing and complicated interpretation.
- a system in which all the steps leading to the results are carried out in the same tube which is based on the amplification of the target DNA, the specific hybridization of a probe (in this case serving as an oligonucleotide primer) with the target DNA, extending the probe with selective addition of an ⁇ S- phosphothioated deoxynucleotide to the 3 'end of the primer complementary to the target DNA; the primer thus elongated being resistant to digestion by an exonuclease, in particular by exonuclease III.
- a probe in this case serving as an oligonucleotide primer
- the probe remains present in the tube only when the following conditions are met: a) hybridization between the probe and the target DNA of the sample, and b) presence of a complementary base in the target DNA allowing the incorporation of the ⁇ S-phosphothioatedésoxynucleotide into the probe; which prevents its degradation by nuclease.
- the key steps of this process are illustrated in the example presented in Figure 1 below.
- the technique described in US 4,656,127 consists in the incorporation of a thio-dNTP which protects from the degradation of the exonuclease.
- the method according to the invention offers the advantage of speed, simplicity of implementation and ease of interpretation of the results.
- tubes A and B allow excellent reliability (presence of a positive control, whatever the genotype to be tested) and a direct interpretation of the results.
- a higher number of tubes can also be used.
- four tubes are used, in order to be able to test the presence of each base on the target DNA. This allows to refine the analysis when the tested base is very polymorphic.
- a second advantage of the method according to the invention is conferred by the attachment of one of the primers to the tube used for the amplification and thus anchoring the amplification products on the walls of the tubes.
- the advantage of this anchoring is to be able to then carry out all the reactions leading to the colored development, including washes in the same tube which in particular avoids the risks of contamination and represents a significant time saving, especially knowing that the use the same solid support for all stages of the process facilitates automation.
- a third advantage of the present invention is to differentiate between homozygous and heterozygous carriers of the targeted mutation thanks to the use of two separate tubes. Indeed, the revelation results in a coloration in only one of the two tubes if the mutation is present in the homozygous state, while the coloration is present in the two tubes if the mutation is present in the heterozygous state. Furthermore, the result can be obtained in 30 to 40 minutes after PCR amplification and does not require any particular heavy environment.
- certain steps can be combined (exonuclease and revelation in particular) in order to reduce the implementation time without modifying the specificity. Thanks to such a method, the detection experiment can be repeated, unlike the technique described in US 4,656,127. Indeed, the use of the solid support makes it possible to conserve the strand of nucleic acid to be analyzed and the exonuclease degrading the unprotected probe, the hybridization and detection step can be repeated in the same tube if necessary.
- the present invention relates to a method allowing the identification of a known mutation or polymorphism in a nucleic sequence comprising the amplification of the region of interest by PCR, this amplification step being advantageously carried out using a primer attached to the wall of two tubes A and B (asymmetric PCR); hybridization of a specific probe designed so that its end is positioned just upstream from the base to be revealed; elongation of this probe by means of a polymerase with a modified nucleotide, advantageously a phosphothionucleotide, in particular an ⁇ S- phosphothioatedésoxynucleotide, complementary to the mutation to be revealed (tube A) and complementary to the normal base corresponding to the mutation to be revealed ( tube B); the action of an exonuclease so that only the elongated probes are not degraded.
- the detection of the presence or absence of a mutation is carried out by direct or indirect revelation of the probe.
- all the stages of the method are carried out in the same tube (from PCR amplification to revelation) so that the presence of a mutation is revealed directly by the appearance of a coloration in the tube used for PCR (see Figure 1 ).
- the presence of the mutation can also be detected by other detection methods, in particular fluorescence, or by using radioactive probes (see below).
- the invention relates to a method for detecting a mutation located in position n in a target nucleic acid, characterized in that it comprises the following steps: a) amplification on at least two solid supports distinct A and B of the region of interest comprising said mutation using at least one primer linked in 5 'to the supports, b) dehybridization of the DNA strands and elimination of the strands in suspension by washing, c) hybridization a probe with the DNA strands linked to solid supports A and B, the 3 ′ end of said probe hybridizing at most to nucleotide n-1 of said strands, d) elongation reaction of the probe hybridized in step c) by incorporation in the 5'-3 'direction of nucleotides complementary to said DNA strands by means of a reaction mixture comprising a DNA polymerase and a nucleotide derivative resistant to degradation by an exonuclease (dNTP *), the reaction mixture uti used for
- the binding of the 5 ′ primer to the supports (step a) is advantageously a sufficiently strong bond so that the DNA remains attached to the support during the various steps of the process. It can be a covalent bond, but also a non-covalent bond, such as an avidin-streptavidin / biotin bond, or an antibody / antigen type bond.
- step c) the probe hybridizing at most to the nucleotide n-1 of said strands means that the probe can also hybridize to n-2, n-3, n-4 ... It will then be necessary therefore provide, during the elongation step (d), the nucleotides complementary to the missing bases in order to allow the elongation of the probe to the mutated base for which the dNTP * is supplied.
- a “probe” is defined as being a nucleotide fragment comprising for example from 10 to 100 nucleotides, in particular from 15 to 35 nucleotides, having a specificity of hybridization under determined conditions to form a hybridization complex with a target nucleic acid.
- the probes according to the invention can carry a labeling agent allowing or improving their detection.
- the probe also serves as a primer in the context of the invention since the objective is to incorporate a nucleotide modified in position n corresponding to the position of the mutation that is sought.
- the 3 ′ end of the probe therefore ends at the maximum and preferably at n-1.
- the probe can be marked by means of a marker chosen, for example, from radioactive isotopes, enzymes, in particular enzymes capable of acting on a chromogenic, fluorigenic or luminescent substrate (in particular a peroxidase or an alkaline phosphatase) or alternatively enzymes producing or using protons (oxidase or hydrolase); chromophoric chemical compounds, chromogenic, fluorigenic or luminescent compounds, nucleotitic base analogs, and ligands such as biotin.
- a marker chosen, for example, from radioactive isotopes, enzymes, in particular enzymes capable of acting on a chromogenic, fluorigenic or luminescent substrate (in particular a peroxidase or an alkaline phosphatase) or alternatively enzymes producing or using protons (oxidase or hydrolase); chromophoric chemical compounds, chromogenic, fluorigenic or luminescent compounds, nucleotitic base analogs, and lig
- the labeling of the probes according to the invention is carried out by elements selected from ligands such as biotin, avidin, streptavidin, dioxygenin, haptens, dyes, luminescent agents such as radioluminescent, chemiluminescent, bioluminescent, fluorescent, phosphorescent agents.
- ligands such as biotin, avidin, streptavidin, dioxygenin, haptens, dyes, luminescent agents such as radioluminescent, chemiluminescent, bioluminescent, fluorescent, phosphorescent agents.
- luminescent agents such as radioluminescent, chemiluminescent, bioluminescent, fluorescent, phosphorescent agents.
- Another possibility is to label the probe with a peptide comprising an epitope recognized by a given antibody. The presence of this antibody can be revealed by means of a second labeled antibody.
- the probe is advantageously labeled with one of the abovementioned molecules, said molecules allowing the direct or indirect appearance of a coloration when the non-degraded probe is present on the support, said coloration being preferably detectable by optical reading or simple observation.
- Optical reading means any measurement of absorption, transmission or emission of light which may possibly be at a specific wavelength either directly from DNA (260 nm for example), or from any marker molecule linked to the probe.
- This definition also includes any measurement of the fluorescence emitted by markers (fluorescein and / or phycoerythrin).
- the presence or absence of the mutation is detected either by optical reading, or by simple observation of a coloration on the solid support.
- the solid support used to anchor the primer can be a plastic material (polystyrene, polycarbonate for example), or nylon or glass, so that this support is a tube, a membrane or a ball on which the region of interest is amplified for its analysis, that is to say the detection of a base change.
- the support is a tube (individual or in a bar or in a plate) used for amplification, and therefore compatible with the various thermal cyclers (Perkin Elmer 9700 for example).
- the tubes can also be any ELISA type tube or plate on which covalent attachment of nucleic acids can be carried out.
- Different methods of immobilizing an oligonucleotide on a support are possible and are described in particular in US 6,030,782. These methods can be a direct immobilization by chemical bond for example or an indirect immobilization (via a linker or a conjugate such as streptavidin for example).
- supports A and B are tubes on which covalent attachment of nucleic acids can be carried out.
- these tubes are Nucleolink TM strips (NUNC, catalog reference No. 248259) which have a special coating allowing the direct covalent attachment of oligonucleotides by their 5 ′ phosphate end (Rasmussen, SR et al., Anal. Biochem , 198: 138-142 (1991)).
- the format of this process is thus the standard 96-well format (12 strips of 8 wells), but the strips being breakable, the desired number of tubes can be used.
- Other formats can be used, in particular if other fixing methods are used. For example, it is possible to attach the nucleic acids by disulfide bridge by following the method recommended in US 6,300,782.
- step d) an ⁇ S-phosphothioatedésoxynucleotide, preferably ⁇ S-dATP, ⁇ S-dTTP, ⁇ S-dCTP, ⁇ S-dGTP, ⁇ S-dUTP or ⁇ S-dITP and in step e) an exonuclease, including exonuclease III.
- exonuclease means any natural or modified enzyme having an exonuclease activity.
- DNA polymerase having a pyrophophorolysis activity in the presence of a high concentration of pyrophosphate, this enzyme adds a pyrophosphate on the last phosphodiester bond and therefore releases the nucleotide at 3 '.
- This product is available from Promega under the brand READIT TM, and variants using a luciferase revealing system is available under the brand READase TM.
- a well receives a DNA, then a probe and the incorporation of only one nucleotide (dNTP *) is allowed. Therefore, at least two tubes are required for each DNA to be tested, one receiving the normal base and the other receiving the mutated base.
- the method described above is characterized in that two tubes are used, one being intended for the detection of the mutated base (tube A) and the other being intended for the detection of the normal base corresponding to said mutated base (tube B).
- several series of tubes A and B can be used, in particular in a 96-well plate and a tube C as a negative control for each series of tubes A and B.
- said dNTP * is an ⁇ S - phosphothioatedésoxynucleotide such as ⁇ S-dATP, ⁇ S-dTTP, ⁇ S-dCTP, ⁇ S-dGTP, ⁇ S-dUTP or ⁇ S-dITP which is incorporated at the 3 ′ end of the probe.
- DNA polymerase is understood to mean any natural or modified enzyme having polymerase activity. Mention may be made, for example, of pol exo- DNAs, in particular T7 or the klenow fragment.
- steps e) and f) are carried out simultaneously in the same reaction mixture comprising said exonuclease and the means necessary to reveal the coloration.
- These means depend on the marker or the ligand which is on the probe.
- Another aspect of the invention relates to a device or kit making it possible to implement the method defined above.
- Such a kit is characterized in that it includes: tubes A and B in which at least one primer making it possible to amplify the region comprising the specific mutation is linked in 5 ′ by a covalent bond, reaction mixtures A and B each comprising a different ⁇ S- phosphothioatedesoxynucleotide selected from ⁇ S-dATP, ⁇ S dTTP, ⁇ S-dCTP, S-dGTP, ⁇ S-dUTP and S-dITP, the reaction mixture used for support A comprising an ⁇ S-phosphothioatedésoxynucleotide complementary to said mutation and the reaction mixture used for support B comprising an S-phosphothioatedésoxynucleotide complementary to the normal base corresponding to said mutation.
- This kit can also comprise at least one element selected from an exonuclease, in particular exonuclease III, a reagent making it possible to reveal the coloration, a DNA polymerase and various buffers or solutions necessary for the implementation of the method.
- the kit according to the invention comprises a series of tubes A and B, each series making it possible to detect a given mutation and tubes C as negative controls.
- Said tubes can be NUNC tubes.
- the invention relates to the use of the method and the kit described above for the detection of gene mutations implicated in diseases, in particular in hereditary genetic diseases, in particular hemochromatosis, anemia sickle cell ⁇ and ⁇ thalassemia, cystic fibrosis, hemophilia, neurodegenerative diseases and mutations in the genes involved in cancer.
- hereditary genetic diseases in particular hemochromatosis, anemia sickle cell ⁇ and ⁇ thalassemia, cystic fibrosis, hemophilia, neurodegenerative diseases and mutations in the genes involved in cancer.
- An exhaustive list of mutations in these genes is given on the following website: ftp://ncbi.nlm.nih.gov/reposito ⁇ -v/OMIM/morbid ⁇ nap
- the method and the kit according to the invention are also useful for studying the polymorphism of genes or any genetic region and for the detection and / or identification of genetically modified organisms (GMOs).
- Figure 1A PCR amplification in solid phase
- An enzymatic reaction catalyzes the elongation of a probe resulting in the insertion of a modified nucleotide, for example an ⁇ S-phosphothioatedésoxynucleotide at the 3 'end of the probe.
- Two reactions in the two tubes A and B are necessary for each sample with the incorporation of a single base to detect the normal genotypes (tube B) and / or mutants (tube A).
- the elongated probe is protected from the degrading action of the exonuclease and a blue color develops during incubation with the substrate.
- the non-elongated probe is eliminated, no coloration is obtained.
- detection can be performed with a FITC-labeled probe and an anti-labeled antibody.
- Figure 1E very easy visual interpretation of the results The results for 4 series of tubes A and B (for 4 individuals or 4 different mutations in the same individual) are presented. Positive results are blue (dark gray in the text) and negatives are colorless. For each individual, whether mutated or normal, a coloration is obtained. In the case of heterozygote, a coloration is obtained in the two wells.
- Figures 2A and 2B detection of C282Y and H63D mutations responsible for hemochromatosis.
- (1) corresponds to the exon of the CFTR gene in which the mutation is found
- Figures 4A, 4B, 4C, 4D, 4E, 4F and 4G detection of 7 mutations responsible for cystic fibrosis.
- FIGS. 5A and 5B detection of the C282Y and H63D mutations responsible for hemochromatosis (preferred method according to the invention in which the degradation and revelation steps are coupled).
- Example 1 protocol for implementing the process according to the invention
- the method according to the present invention makes it possible to determine the genotype of a sample, the latter being previously amplified using a primer fixed to the wall of the tube.
- the tubes used are the Nucleolink strips (NUNC), the fixing of the primer is carried out according to the indications of the supplier.
- PCR buffers dNTP, primer A 1 ⁇ M final, primer B 0.12 ⁇ M final, Taq polymerase and DNA to be tested.
- the amplification products obtained in the liquid phase can be discarded or kept for analysis on a 1.5% agarose gel stained with ethidium bromide.
- TMB substrate Tetramethylbenzidine - Sigma
- Reading can then be done with the naked eye; a blue color appearing in the positive wells. It is also possible to read the optical density at 655 nm using a microplate reader or at 450 nm if the reaction has been stopped.
- the genotype of a given sample can be determined: by reading with the naked eye: a blue color appears in the positive wells and the negative wells remain colorless.
- the four possible coloring benefits are described below:
- Example 2 diagnosis of hemochromatosis, detection of mutations C282Y and H63D responsible for hemochromatosis.
- H63D in the case of the normal solution
- ⁇ thiodATP mutant base for C282Y
- ⁇ thiodCTP mutant base for H63D
- Mutant case incorporation of an ⁇ S-dATP, region of SNP C282Y and its complementary region, included in the region amplified by the primers SEQ ID No. 1 and SEQ ID No. 2, the probe SEQ ID No. 3 being underlined, the polymorphic base being in bold.
- Mutant case incorporation of an ⁇ S-dCTP, region of SNP H63D and its complementary region, included in the region amplified by the primers SEQ ID No. 8 and SEQ ID No. 9, the probe SEQ ID No. 10 being underlined, the polymorphic base being in bold.
- Example 3 Diagnosis of cystic fibrosis, detection of seven mutations responsible for cystic fibrosis.
- Example 4 Improvement of the protocol, coupling of the exonuclease digestion and revelation steps.
- Steps 1 to 4 are identical to those of Example 1, only the following steps are modified so that digestion with Exonuclease III and revelation by the antibody are carried out in a single step.
- - Deposit per well 25 ⁇ l of solution containing 0.01 U of Exonuclease III (New England Biolabs) in its buffer, 2.5 ⁇ l of anti-FITC-POD antibody (Boehringer Mannheim) l / 200th in PBS-BSA 3 % and 0.25 ⁇ l Tween 20; Incubate 10 minutes at 37 ° C;
- Steps 1 to 2 are identical to those of Example I, only the following steps are modified so that the final development is carried out using streptavidin, the probe having been previously coupled to a biotin. 3. Hybridization and elongation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/344,093 US20040076969A1 (en) | 2000-08-08 | 2001-08-08 | Method for detecting known mutations in tube |
AU2001284121A AU2001284121A1 (en) | 2000-08-08 | 2001-08-08 | Method for detecting known mutations in tube |
EP01963075A EP1409719A1 (fr) | 2000-08-08 | 2001-08-08 | Procede de detection de mutations connues en tube |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/10425 | 2000-08-08 | ||
FR0010425A FR2812885A1 (fr) | 2000-08-08 | 2000-08-08 | Procede de detection de mutations connues en tube |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002012557A1 true WO2002012557A1 (fr) | 2002-02-14 |
Family
ID=8853392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/002574 WO2002012557A1 (fr) | 2000-08-08 | 2001-08-08 | Procede de detection de mutations connues en tube |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040076969A1 (fr) |
EP (1) | EP1409719A1 (fr) |
AU (1) | AU2001284121A1 (fr) |
FR (1) | FR2812885A1 (fr) |
WO (1) | WO2002012557A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111647953A (zh) * | 2020-07-09 | 2020-09-11 | 广州赛乐斯密医学科技有限公司 | 用于检测地中海贫血基因突变的高通量文库构建试剂盒及文库构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656127A (en) * | 1983-04-22 | 1987-04-07 | Amersham International Plc. | Method of detecting mutations in DNA and RNA |
US5762876A (en) * | 1991-03-05 | 1998-06-09 | Molecular Tool, Inc. | Automatic genotype determination |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700642A (en) * | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
-
2000
- 2000-08-08 FR FR0010425A patent/FR2812885A1/fr not_active Withdrawn
-
2001
- 2001-08-08 WO PCT/FR2001/002574 patent/WO2002012557A1/fr not_active Application Discontinuation
- 2001-08-08 US US10/344,093 patent/US20040076969A1/en not_active Abandoned
- 2001-08-08 AU AU2001284121A patent/AU2001284121A1/en not_active Abandoned
- 2001-08-08 EP EP01963075A patent/EP1409719A1/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656127A (en) * | 1983-04-22 | 1987-04-07 | Amersham International Plc. | Method of detecting mutations in DNA and RNA |
US5762876A (en) * | 1991-03-05 | 1998-06-09 | Molecular Tool, Inc. | Automatic genotype determination |
Also Published As
Publication number | Publication date |
---|---|
EP1409719A1 (fr) | 2004-04-21 |
FR2812885A1 (fr) | 2002-02-15 |
AU2001284121A1 (en) | 2002-02-18 |
US20040076969A1 (en) | 2004-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008217678B2 (en) | Method and test kit for determining the amounts of target sequences and nucleotide variations therein | |
US5948899A (en) | Compositions for homogenous protection assay | |
CA2401867A1 (fr) | Nouvelles puces a adn | |
US5837465A (en) | Luciferase labelling method | |
FR2710075A1 (fr) | Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal. | |
US20050287549A1 (en) | Method of genetic testing | |
EP0827552B1 (fr) | Detection d'une sequence nucleotidique avec amplification de signal | |
Lim et al. | Detection of Atrazine Based on the SPR Determination of P450 mRNA Levels in Saccharomyces c erevisiae | |
EP0362042B1 (fr) | Procédé d'analyse d'une séquence spécifique d'ADN ou d'ARN, réactifs et nécessaires pour sa mise en oeuvre | |
WO2002012557A1 (fr) | Procede de detection de mutations connues en tube | |
CN101292045A (zh) | 核酸分析方法 | |
EP0871766A1 (fr) | Procede de detection de variations dans des sequences d'acide nucleique | |
US20090011514A1 (en) | Dna Crosslinking for Primer Extension Assays | |
WO1997046700A1 (fr) | Sondes nucleotidiques et procede pour determiner le typage hla dqb1 | |
CA2175515A1 (fr) | Fragment nucleotidique de l'arn ribosomique 16s de corynebacteries, sondes et amorces derivees, reactif et procede de detection | |
FR2816958A1 (fr) | Procede d'analyse de la predisposition genetique d'un patient au diabete insulino-dependant, dispositif adapte a sa mise en oeuvre et jeu d'amorces d'amplification adapte a un tel procede | |
JP2003522527A (ja) | 一塩基多型の検出 | |
AU680988B2 (en) | Hydridisation assay and reagents | |
WO2017042509A1 (fr) | Procédé et dispositif pour le genotypage de snp | |
EP0353124A1 (fr) | Procédé de marquage d'une sonde nucléique et trousse de réactifs pour la mise en oeuvre de ce procédé | |
EP1330542A2 (fr) | Methode rapide de detection d'organismes dans un echantillon | |
CA2610057A1 (fr) | Methode et trousses de detection de mutations associees a maladies genetiques recessives | |
FR2920159A1 (fr) | Methode et reactifs pour la quantification, la comparaison et l'identification d'alleles sur support solide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001963075 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10344093 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001963075 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001963075 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |